Form4insider filings, from the source

SEC Form 4 · accession 0001192482-19-000034

Recro Pharma, Inc. · REPH

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Michael Celano
Officer — Chief Operating Officer
Period of report
Jan 18, 2019
Accepted (ET)
Jan 23, 2019 · 4:06 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001588972

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF1Jan 18, 2019A12,672$0.00A39,445D
Common StockF2Jan 18, 2019M6,400—A45,845D
Common StockF3Jan 18, 2019F1,782$7.99D44,063D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Employee Stock Option (right to buy)F4$7.99Jan 18, 2019A60,592A—Jan 18, 2029Common Stock60,59260,592D
Restricted Stock UnitsF2,F5—Jan 18, 2019M6,400D——Common Stock6,40012,800D

Explanation of responses